These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18309904)

  • 1. Pharmacological intervention to the inflammatory response from decompression sickness in rats.
    Little T; Butler BD
    Aviat Space Environ Med; 2008 Feb; 79(2):87-93. PubMed ID: 18309904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dibutyryl cAMP effects on thromboxane and leukotriene production in decompression-induced lung injury.
    Little TM; Butler BD
    Undersea Hyperb Med; 1997 Sep; 24(3):185-91. PubMed ID: 9308142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circadian study of decompression sickness symptoms and response-associated variables in rats.
    Butler BD; Little TM; Sothern RB; Smolensky MH
    Chronobiol Int; 2010 Jan; 27(1):138-60. PubMed ID: 20205563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperbaric oxygen pre-breathe modifies the outcome of decompression sickness.
    Butler BD; Little T; Cogan V; Powell M
    Undersea Hyperb Med; 2006; 33(6):407-17. PubMed ID: 17274310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into IgE-mediated lung inflammation derived from a study employing a 5-lipoxygenase inhibitor.
    Kane GC; Tollino M; Pollice M; Kim CJ; Cohn J; Murray JJ; Dworski R; Sheller J; Fish JE; Peters SP
    Prostaglandins; 1995 Jul; 50(1):1-18. PubMed ID: 8588068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of 5-lipoxygenase inhibitors, zileuton, A-78773 and ICI-D-2138 in an ionophore (A-23187)-induced pleural inflammation model in the rat.
    Rao TS; Currie JL; Shaffer AF; Isakson PC
    Life Sci; 1993; 53(9):PL147-52. PubMed ID: 8394967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simvastatin decreases incidence of decompression sickness in rats.
    Zhang K; Wang D; Xu J; Li R; Cai Z; Liu K; Zheng J; Denoble PJ; Fang Y; Xu W
    Undersea Hyperb Med; 2015; 42(2):115-23. PubMed ID: 26094286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effect of zileuton, a 5-lipoxygenase inhibitor, against nociceptive paradigms in mice and rats.
    Singh VP; Patil CS; Kulkarni SK
    Pharmacol Biochem Behav; 2005 Jul; 81(3):433-9. PubMed ID: 15935457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 5-lipoxygenase inhibitor zileuton blocks antigen-induced late airway responses, inflammation and airway hyperresponsiveness in allergic sheep.
    Abraham WM; Ahmed A; Cortes A; Sielczak MW; Hinz W; Bouska J; Lanni C; Bell RL
    Eur J Pharmacol; 1992 Jul; 217(2-3):119-26. PubMed ID: 1330588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiopulmonary changes with moderate decompression in rats.
    Butler BD; Robinson R; Little T; Chelly JE; Doursout MF
    Undersea Hyperb Med; 1996 Jun; 23(2):83-9. PubMed ID: 8840476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 5-lipoxygenase inhibitor zileuton on airway responses to inhaled swine house dust in healthy subjects.
    Larsson BM; Kumlin M; Sundblad BM; Larsson K; Dahlén SE; Palmberg L
    Respir Med; 2006 Feb; 100(2):226-37. PubMed ID: 15939582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.
    McMillan RM; Spruce KE; Crawley GC; Walker ER; Foster SJ
    Br J Pharmacol; 1992 Dec; 107(4):1042-7. PubMed ID: 1334748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clopidogrel reduces the inflammatory response of lung in a rat model of decompression sickness.
    Bao XC; Chen H; Fang YQ; Yuan HR; You P; Ma J; Wang FF
    Respir Physiol Neurobiol; 2015 Jun; 211():9-16. PubMed ID: 25784626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological intervention against bubble-induced platelet aggregation in a rat model of decompression sickness.
    Pontier JM; Vallée N; Ignatescu M; Bourdon L
    J Appl Physiol (1985); 2011 Mar; 110(3):724-9. PubMed ID: 21212250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of 5-lipoxygenase inhibitors in biochemical and functional in vivo assays.
    Smith WG; Shaffer AF; Currie JL; Thompson JM; Kim S; Rao T; Isakson PC
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1332-8. PubMed ID: 8531100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation.
    Kirchner T; Argentieri DC; Barbone AG; Singer M; Steber M; Ansell J; Beers SA; Wachter MP; Wu W; Malloy E; Stewart A; Ritchie DM
    J Pharmacol Exp Ther; 1997 Aug; 282(2):1094-101. PubMed ID: 9262379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of 5-lipoxygenase and cyclooxygenase blockade on porcine hemodynamics during continuous infusion of platelet-activating factor.
    Olson NC; Kruse-Elliott KT; Johnson LW
    Prostaglandins Leukot Essent Fatty Acids; 1993 Aug; 49(2):549-59. PubMed ID: 8415804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cysteinyl-leukotriene-1 receptor antagonist zafirlukast is a potent secretagogue in rat and human airways.
    Schmidt R; Staats P; Groneberg DA; Wagner U
    Eur J Pharmacol; 2005 Dec; 527(1-3):150-6. PubMed ID: 16310765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma.
    Wenzel SE; Trudeau JB; Kaminsky DA; Cohn J; Martin RJ; Westcott JY
    Am J Respir Crit Care Med; 1995 Sep; 152(3):897-905. PubMed ID: 7663802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors.
    Drazen J
    Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 2):S233-7; discussion S247-8. PubMed ID: 9647605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.